Mark William Geraci
Physician at Hannibal Way, Denver, CO
License number
Colorado 30744
Issued Date
Apr 11, 1991
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
5093 S Hannibal Way S Hannibal Wy, Denver, CO 80015
Personal information
See more information about Mark William Geraci at radaris.comName
Address
Phone
5093 S Hannibal Way, Aurora, CO 80015
14798 Wagontrail Ave, Aurora, CO 80015
4200 9Th Ave, Denver, CO 80220
5093 Hannibal St, Aurora, CO 80015
5093 S Hannibal Way, Aurora, CO 80015
Professional information
Dr. Mark W Geraci, Aurora CO - MD (Doctor of Medicine)
Specialties:
Critical Care Medicine, Pulmonology
Address:
12605 E 16Th Ave, Aurora 80045
(720) 848-0748 (Phone)
(720) 848-0748 (Phone)
Certifications:
Critical Care Medicine, 2012, Internal Medicine, 2002, Pulmonary Disease, 2012
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
12605 E 16Th Ave, Aurora 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
Education:
Medical School
Johns Hopkins University School Of Medicine
Graduated: 1987
Brigham and Women's Hospital/Massachusetts General Hospital Program
University Of Colorado (University Hospital) Program
Johns Hopkins University School Of Medicine
Graduated: 1987
Brigham and Women's Hospital/Massachusetts General Hospital Program
University Of Colorado (University Hospital) Program
Mark W Geraci, Aurora CO
Specialties:
Pulmonologist
Address:
1635 Aurora Ct, Aurora, CO 80045
Education:
Johns Hopkins University, School of Medicine - Doctor of Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Pulmonary Disease and Critical Care Medicine (Internal Medicine)
Massachusetts General Hospital - Residency - Family Medicine
University of Colorado Hospital-Anschutz Inpatient Pavilion - Fellowship - Pulmonary Disease and Critical Care Medicine (Internal Medicine)
Massachusetts General Hospital - Residency - Family Medicine
Board certifications:
American Board of Internal Medicine Sub-certificate in Critical Care Medicine (Internal Medicine), American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)
Professor At Uc Denver
Position:
Professor at UC Denver
Location:
Greater Denver Area
Industry:
Higher Education
Work:
UC Denver
-
Professor
Mark Geraci, Aurora CO
Work:
University of Colorado Hospital
12605 E 16Th Ave, Aurora, CO 80045
12605 E 16Th Ave, Aurora, CO 80045
Diagnosis Of Disease And Monitoring Of Therapy Using Gene Expression Analysis Of Peripheral Blood Cells
US Patent:
2006001, Jan 26, 2006
Filed:
May 3, 2005
Appl. No.:
11/122329
Inventors:
Mark Geraci - Aurora CO, US
Todd Bull - Denver CO, US
Norbert Voelkel - Denver CO, US
Christopher Coldren - Denver CO, US
Todd Bull - Denver CO, US
Norbert Voelkel - Denver CO, US
Christopher Coldren - Denver CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
International Classification:
C12Q 1/68
US Classification:
435006000
Abstract:
Disclosed are methods to diagnose a patient that has a pulmonary disease, and particularly, pulmonary arterial hypertension, using biomarkers that are differentially regulated in the peripheral blood cells of patients with such disease as compared to individuals that do not have the disease. Also disclosed are methods to diagnose a patient that has idiopathic pulmonary arterial hypertension as compared to pulmonary arterial hypertension associated with secondary causes. Pluralities of nucleotides and antibodies useful in the invention are described. Methods of identifying compounds with the potential to treat pulmonary arterial hypertension (PAH) are also described.
Gefitinib Sensitivity-Related Gene Expression And Products And Methods Related Thereto
US Patent:
2007027, Nov 22, 2007
Filed:
Jan 24, 2005
Appl. No.:
10/587052
Inventors:
Paul Bunn Jr. - Evergreen CO, US
Christopher Coldren - Denver CO, US
Wilbur Franklin - Denver CO, US
Mark Geraci - Aurora CO, US
Barbara Helfrich - Lakewood CO, US
Fred Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir Witta - Greenwood Village CO, US
Christopher Coldren - Denver CO, US
Wilbur Franklin - Denver CO, US
Mark Geraci - Aurora CO, US
Barbara Helfrich - Lakewood CO, US
Fred Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir Witta - Greenwood Village CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
International Classification:
A61K 31/00, A61P 35/00, C12Q 1/02, C12Q 1/68
US Classification:
514789000, 435029000, 435006000
Abstract:
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Gefitinib Sensitivity-Related Gene Expression And Products And Methods Related Thereto
US Patent:
2008011, May 15, 2008
Filed:
Jul 23, 2007
Appl. No.:
11/781946
Inventors:
Paul A. BUNN - Steamboat Springs CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Indianapolis IN, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Indianapolis IN, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Boulder CO
International Classification:
C40B 30/04, G01N 33/574, C12Q 1/68
US Classification:
506 9, 435 723, 435 6
Abstract:
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Gefitnib Sensitivity-Related Gene Expression And Products And Methods Related Thereto
US Patent:
2010019, Aug 5, 2010
Filed:
Jul 23, 2008
Appl. No.:
12/670052
Inventors:
Paul A. Bunn - Evergreen CO, US
Christopher D. Coldren - Denver CO, US
Wilbur A. Franklin - Denver CO, US
Mark W. Geraci - Aurora CO, US
Barbara A. Helfrich - Lakewood CO, US
Fred R. Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir E. Witta - Greenwood Village CO, US
Christopher D. Coldren - Denver CO, US
Wilbur A. Franklin - Denver CO, US
Mark W. Geraci - Aurora CO, US
Barbara A. Helfrich - Lakewood CO, US
Fred R. Hirsch - Denver CO, US
Razvan Lapadat - Denver CO, US
Michio Sugita - Centennial CO, US
Samir E. Witta - Greenwood Village CO, US
International Classification:
A61K 39/395, C12Q 1/68, A61K 31/5377, A61K 31/517, A61K 31/497
US Classification:
4241331, 435 6, 5142345, 5142664, 51425218, 4241411
Abstract:
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Gefitnib Sensitivity-Related Gene Expression And Products And Methods Related Thereto
US Patent:
2012017, Jul 12, 2012
Filed:
Mar 12, 2012
Appl. No.:
13/418004
Inventors:
Paul A. BUNN - Evergreen CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Denver CO, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US
Christopher D. COLDREN - Denver CO, US
Wilbur A. FRANKLIN - Denver CO, US
Mark W. GERACI - Aurora CO, US
Barbara A. HELFRICH - Lakewood CO, US
Fred R. HIRSCH - Denver CO, US
Razvan LAPADAT - Denver CO, US
Michio SUGITA - Centennial CO, US
Samir E. WITTA - Greenwood Village CO, US
International Classification:
A61K 39/395, A61K 31/517, A61P 35/00, C40B 30/00, G01N 33/566, G01N 21/64, G01N 21/76, G01N 27/62, A61K 31/5377, C12Q 1/02
US Classification:
4241331, 4241421, 5142345, 5142664, 435 29, 435 723, 506 7
Abstract:
Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to EGFR inhibitors, and products and processes related thereto. In one embodiment, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
Treatment Of Copd
US Patent:
2010004, Feb 25, 2010
Filed:
Dec 4, 2007
Appl. No.:
12/517787
Inventors:
Mark W. Geraci - Aurora CO, US
Patrick S. Nana-Sinkam - Columbus OH, US
Patrick S. Nana-Sinkam - Columbus OH, US
Assignee:
The Regents of the University of Colorado, A Body Corporate - Denver CO
International Classification:
A61K 31/343, A61K 31/19
US Classification:
514468, 514573
Abstract:
The present invention provides methods for treating chronic obstructive pulmonary disease. In some embodiments of the invention, methods for treating COPD comprise administering PGIor a prostacyclin analog to a subject in need of such treatment.